Mavacamten Cuts Heart Obstruction in Teens With Hypertrophic Cardiomyopathy, Trial Shows

For a teenager with hypertrophic cardiomyopathy, gym class can mean dizziness, chest pain, or a sudden trip to the emergency room. Open-heart surgery has long been the most definitive fix for adolescents whose symptoms do not respond to beta-blockers or other older medications. A trial published Saturday in the New England Journal of Medicine now offers a third possibility: a pill that directly targets the muscle mechanics driving the disease.

The study, called SCOUT-HCM, found that adolescents between 12 and 17 who took mavacamten saw the pressure gradient across their left ventricular outflow tract fall by a mean of 48.5 millimeters of mercury over 28 weeks. Teenagers who took a placebo saw their gradient change by just 0.5 mm Hg. That difference matters because the outflow gradient is a direct measure of how hard the heart must work to push blood out; reducing it can translate to fewer episodes of breathlessness, greater exercise capacity, and a lower likelihood of being referred for septal myectomy, the open-heart procedure that widens the narrowed channel by removing part of the thickened muscle wall.

Joseph Rossano, MD, MS, chief of the Division of Cardiology at Children's Hospital of Philadelphia and the study's lead author, called the findings potentially "transformative." Before this trial, clinicians treating adolescents with obstructive HCM had no targeted option designed for this age group; they relied on medications developed for adults or, when those failed, surgical intervention. Mavacamten is a cardiac myosin inhibitor that works differently from those older drugs: rather than managing downstream symptoms like heart rate or blood pressure, it quiets the overactive muscle protein that causes the wall to thicken and obstruct the outflow tract in the first place.

Blood biomarkers reinforced the point. Markers of myocardial injury fell in the 23 teenagers who received mavacamten and rose in the 21 who received placebo, suggesting the drug's benefit runs deeper than pressure readings alone. Safety profiles were similar between the two groups, and all participants met the study's predefined safety thresholds across the full 28-week period. Results were also presented at the American College of Cardiology's Annual Scientific Session in New Orleans on the same day the paper went live.

There are real caveats. The trial enrolled 44 adolescents total, a number that reflects the relative rarity of symptomatic obstructive HCM in this age group but that also limits how confidently regulators can generalize the findings. Mavacamten requires regular echocardiographic monitoring in adults because it can, in a small number of patients, suppress cardiac function too aggressively, and it remains unclear how growing adolescent hearts respond over years rather than months. Dosing protocols calibrated for adult body weights will require pediatric-specific refinement.

If the FDA expands mavacamten's label to include adolescents, it would become the first targeted, pediatric-specific therapy approved for obstructive HCM. Until that happens, any prescribing in this age group would be off-label, raising immediate questions about whether insurers will cover a drug that currently carries no pediatric indication. HCM is the most common inherited heart disease, and for families watching a teenager's cardiac reserve and athletic eligibility erode in tandem, the gap between promising trial data and an insurer's approval letter can feel as obstructive as the condition itself.